Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data

PartnershipPF-08046031Positive

AI Analysis

Summary

Pfizer grants Medicus Pharma co-development rights to PF-08046031, a CD228-targeted antibody-drug conjugate originally derived from Seagen. The article also mentions updates from Novartis and RevMed regarding lung cancer data.

Outcome Details

Pfizer grants Medicus Pharma co-development rights to CD228-targeted antibody-drug conjugate

Importance:6/10

Sentiment:

0.30

partnershiplicensingADCantibody-drug conjugateCD228-targeted

Related Companies

$PFE $MDCXW $PFE $NVS

Read the original article

Published by Endpoints News on September 3, 2026 3:19 PM

Read Original